Cargando…

CD1C is associated with breast cancer prognosis and immune infiltrates

BACKGROUND: The tumor microenvironment (TME) in breast cancer plays a vital role in occurrence, development, and therapeutic responses. However, immune and stroma constituents in the TME are major obstacles to understanding and treating breast cancer. We evaluated the significance of TME-related gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiao, Zhang, Jianzhong, Lei, Xinhan, Yang, Lei, Li, Wanwan, Zheng, Lu, Zhang, Shuai, Ding, Yihan, Shi, Jianing, Zhang, Lei, Li, Jia, Tang, Tong, Jia, WenJun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905770/
https://www.ncbi.nlm.nih.gov/pubmed/36755259
http://dx.doi.org/10.1186/s12885-023-10558-2
_version_ 1784883872290308096
author Chen, Xiao
Zhang, Jianzhong
Lei, Xinhan
Yang, Lei
Li, Wanwan
Zheng, Lu
Zhang, Shuai
Ding, Yihan
Shi, Jianing
Zhang, Lei
Li, Jia
Tang, Tong
Jia, WenJun
author_facet Chen, Xiao
Zhang, Jianzhong
Lei, Xinhan
Yang, Lei
Li, Wanwan
Zheng, Lu
Zhang, Shuai
Ding, Yihan
Shi, Jianing
Zhang, Lei
Li, Jia
Tang, Tong
Jia, WenJun
author_sort Chen, Xiao
collection PubMed
description BACKGROUND: The tumor microenvironment (TME) in breast cancer plays a vital role in occurrence, development, and therapeutic responses. However, immune and stroma constituents in the TME are major obstacles to understanding and treating breast cancer. We evaluated the significance of TME-related genes in breast cancer. METHODS: Invasive breast cancer (BRCA) samples were retrieved from the TCGA and GEO databases. Stroma and immune scores of samples as well as the proportion of tumor infiltrating immune cells (TICs) were calculated using the ESTIMATE and CIBERSORT algorithms. TME-related differentially expressed genes (DEGs) were analyzed by a protein interaction (PPI) network and univariate Cox regression to determine CD1C as a hub gene. Subsequently, the prognostic value of CD1C, its response to immunotherapy, and its mechanism in the TME were further studied. RESULTS: In BRCA, DEGs were determined to identify CD1C as a hub gene. The expression level of CD1C in BRCA patients was verified based on the TCGA database, polymerase chain reaction (PCR) results, and western blot analysis. Immunohistochemical staining (IHC) results revealed a correlation between prognosis, clinical features, and CD1C expression in BRCA. Enrichment analysis of GSEA and GSVA showed that CD1C participates in immune-associated signaling pathways. CIBERSORT showed that CD1C levels were associated with tumor immune infiltrating cells (TILs), such as different kinds of T cells. Gene co-expression analysis showed that CD1C and the majority of immune-associated genes were co-expressed in BRCA. In renal cell carcinoma, patients with a high expression of CD1C had a better immunotherapy effect. CONCLUSION: CD1C is an important part of the TME and participates in immune activity regulation in breast tumors. CD1C is expected to become a prognostic marker and a new treatment target for breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10558-2.
format Online
Article
Text
id pubmed-9905770
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99057702023-02-08 CD1C is associated with breast cancer prognosis and immune infiltrates Chen, Xiao Zhang, Jianzhong Lei, Xinhan Yang, Lei Li, Wanwan Zheng, Lu Zhang, Shuai Ding, Yihan Shi, Jianing Zhang, Lei Li, Jia Tang, Tong Jia, WenJun BMC Cancer Research BACKGROUND: The tumor microenvironment (TME) in breast cancer plays a vital role in occurrence, development, and therapeutic responses. However, immune and stroma constituents in the TME are major obstacles to understanding and treating breast cancer. We evaluated the significance of TME-related genes in breast cancer. METHODS: Invasive breast cancer (BRCA) samples were retrieved from the TCGA and GEO databases. Stroma and immune scores of samples as well as the proportion of tumor infiltrating immune cells (TICs) were calculated using the ESTIMATE and CIBERSORT algorithms. TME-related differentially expressed genes (DEGs) were analyzed by a protein interaction (PPI) network and univariate Cox regression to determine CD1C as a hub gene. Subsequently, the prognostic value of CD1C, its response to immunotherapy, and its mechanism in the TME were further studied. RESULTS: In BRCA, DEGs were determined to identify CD1C as a hub gene. The expression level of CD1C in BRCA patients was verified based on the TCGA database, polymerase chain reaction (PCR) results, and western blot analysis. Immunohistochemical staining (IHC) results revealed a correlation between prognosis, clinical features, and CD1C expression in BRCA. Enrichment analysis of GSEA and GSVA showed that CD1C participates in immune-associated signaling pathways. CIBERSORT showed that CD1C levels were associated with tumor immune infiltrating cells (TILs), such as different kinds of T cells. Gene co-expression analysis showed that CD1C and the majority of immune-associated genes were co-expressed in BRCA. In renal cell carcinoma, patients with a high expression of CD1C had a better immunotherapy effect. CONCLUSION: CD1C is an important part of the TME and participates in immune activity regulation in breast tumors. CD1C is expected to become a prognostic marker and a new treatment target for breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10558-2. BioMed Central 2023-02-08 /pmc/articles/PMC9905770/ /pubmed/36755259 http://dx.doi.org/10.1186/s12885-023-10558-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Xiao
Zhang, Jianzhong
Lei, Xinhan
Yang, Lei
Li, Wanwan
Zheng, Lu
Zhang, Shuai
Ding, Yihan
Shi, Jianing
Zhang, Lei
Li, Jia
Tang, Tong
Jia, WenJun
CD1C is associated with breast cancer prognosis and immune infiltrates
title CD1C is associated with breast cancer prognosis and immune infiltrates
title_full CD1C is associated with breast cancer prognosis and immune infiltrates
title_fullStr CD1C is associated with breast cancer prognosis and immune infiltrates
title_full_unstemmed CD1C is associated with breast cancer prognosis and immune infiltrates
title_short CD1C is associated with breast cancer prognosis and immune infiltrates
title_sort cd1c is associated with breast cancer prognosis and immune infiltrates
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905770/
https://www.ncbi.nlm.nih.gov/pubmed/36755259
http://dx.doi.org/10.1186/s12885-023-10558-2
work_keys_str_mv AT chenxiao cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates
AT zhangjianzhong cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates
AT leixinhan cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates
AT yanglei cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates
AT liwanwan cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates
AT zhenglu cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates
AT zhangshuai cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates
AT dingyihan cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates
AT shijianing cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates
AT zhanglei cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates
AT lijia cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates
AT tangtong cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates
AT jiawenjun cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates